In the present study piroxicam loaded starch nanoparticles were prepared to enhance the solubility of piroxicam by nanoprecipitation technique. The preparation of nanoparticles was carried out as per central composite experimental design protocol, having concentration of starch and drug as independent variables and particle size and polydispersity index (PdI) as dependent variables. The particle size and PdI of piroxicam loaded starch nanoparticles was found to be between 282–870 nm and 0.339–0.772, respectively. After the characterization by FT-IR, TGA, XRD and SEM studies, the optimized batch was evaluated for in-vitro release study, anti-inflammatory activity and anti-oxidant activity. The in-vitro anti-inflammatory activity of piroxicam loaded starch nanoparticles was found to be more than the pure drug piroxicam whereas the anti-oxidant activity of starch is found greater than starch nanoparticles. In-vitro release study showed 98.8% release in 2 h dissolution study following supercase II transport mechanism of drug release.

在本研究中，通过纳米沉淀技术制备了负载吡罗昔康的淀粉纳米颗粒，以提高吡罗昔康的溶解度。纳米粒子的制备按照中心复合实验设计方案进行，以淀粉和药物浓度为自变量，粒径和多分散指数（PdI）为因变量。发现负载吡罗昔康的淀粉纳米颗粒的粒径和 PdI 分别在 282-870 nm 和 0.339-0.772 之间。在通过 FT-IR、TGA、XRD 和 SEM 研究表征后，对优化后的批次进行体外释放研究、抗炎活性和抗氧化活性评估。载有吡罗昔康的淀粉纳米颗粒的体外抗炎活性被发现高于纯药物吡罗昔康，而淀粉的抗氧化活性大于淀粉纳米颗粒。体外释放研究表明，在药物释放的超级酶 II 转运机制后的 2 小时溶出研究中，98.8% 的释放。